Premium
Fluorescent nanoparticle‐mediated semiquantitative MYC protein expression analysis in morphologically diffuse large B‐cell lymphoma
Author(s) -
Takayanagi Natsuko,
Momose Shuji,
Kikuchi Jun,
Tanaka Yuka,
Anan Tomoe,
Yamashita Takahisa,
Higashi Morihiro,
Tokuhira Michihide,
Kizaki Masahiro,
Tamaru Junichi
Publication year - 2021
Publication title -
pathology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
eISSN - 1440-1827
pISSN - 1320-5463
DOI - 10.1111/pin.13131
Subject(s) - bcl6 , diffuse large b cell lymphoma , immunohistochemistry , fluorescence in situ hybridization , lymphoma , in situ hybridization , cancer research , pathology , biology , gene expression , protein expression , gene , microbiology and biotechnology , medicine , b cell , antibody , immunology , germinal center , genetics , chromosome
The current World Health Organization (WHO) classification defines a new disease entity of high‐grade B‐cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, making fluorescence in situ hybridization (FISH) screening for these genes mandatory. In addition, the prognostic significance of MYC expression was reported, with a cut‐off value of 40%. However, interobserver discrepancies arise due to the heterogeneous intensity of MYC expression by immunohistochemistry. Moreover, a cut‐off value of positivity for MYC protein in diffuse large B‐cell lymphoma (DLBCL) varies among studies at present. Here, we applied a high‐sensitivity semiquantitative immunohistochemical technique using fluorescent nanoparticles called phosphor‐integrated dots (PID) to evaluate the MYC expression in 50 de novo DLBCL cases, and compared it with the conventional diaminobenzidine (DAB)‐developing system. The high MYC expression detected by the PID‐mediated system predicted poor overall survival in DLBCL patients. However, we found no prognostic value of MYC protein expression for any cut‐off value by the DAB‐developing system, even if the intensity was considered. These results indicate that the precise evaluation of MYC protein expression can clarify the prognostic values in DLBCL, irrespective of MYC rearrangement.